KIN Profile
Kindred
Biosciences, Inc. (KIN) is a biopharmaceutical company that focuses on
the development of novel therapies for pets. The company is
headquartered in Burlingame, California, and was founded in 2012.
Kindred Biosciences is developing a pipeline of drugs for pets,
including treatments for osteoarthritis, allergic dermatitis, and
cancer. The company's lead product candidate is Mirataz, a transdermal
gel formulation for the management of weight loss in cats. Mirataz
received FDA approval in 2018 and is the first FDA-approved
transdermal medication for cats.
The company's other product
candidates include Zimeta, a non-steroidal anti-inflammatory drug for
the control of fever in horses, and KIND-012, a monoclonal antibody
for the treatment of atopic dermatitis in dogs. In addition, Kindred
Biosciences is developing a pipeline of biosimilars and novel
biologics for the treatment of a variety of animal diseases.
Kindred Biosciences is focused on providing innovative and effective
therapies for pets and their owners. With a growing pipeline of
product candidates and a commitment to scientific excellence, the
company is well-positioned to make a significant impact on the animal
healt
|
